Avecia Biotechnology has launched of its OliGO- Faster, Smarter, Better^SM development program. The program “formalizes Avecia’s extensive process knowledge into an easily accessible parameter library,” according to a company statement.

OliGO is pre-designed to provide a streamlined path from development to cGMP manufacturing; the program aligns small scale models with production capabilities to minimize risk and increase cost efficiencies. Combined with Avecia’s small and intermediate pre-clinical production capabilities, OliGO offers a cost effective and well tested route to quickly deliver non-cGMP material, said the company. The OliGO parameters can also be used as an advanced starting point for development activities, providing clients with the opportunity to bypass initial development work, and move directly to fine tuning a process for optimal purity and yield.

According to a company statement, “Avecia maintains the world’s largest library of oligo process and manufacturing data at scale, drawing from nearly 20 years of experience. Teams of engineers, development chemists, and manufacturing experts have worked together to identify the very best of the process parameters for all our oligo classes, and to formalize them into our OliGO advanced development program.”

Dr. Emma Wright, Avecia’s senior director Process Development, remarked, “Avecia’s process development team is pleased to offer OliGO in conjunction with their extensive service portfolio, including the tech transfer of sequences at all phases of development- from pre-clinical to approved commercial oligonucleotide therapeutics.”